Is there any FDA‑approved medication for reducing cocaine cravings?

No FDA-Approved Medications Exist for Cocaine Cravings

There are currently no FDA-approved medications for treating cocaine use disorder or reducing cocaine cravings 1, 2, 3, 4. This represents a critical unmet need in addiction medicine, leaving clinicians to navigate off-label options with limited evidence.

Most Promising Off-Label Options

While no medications have FDA approval, several agents show potential based on systematic reviews and meta-analyses:

Medications with Low-Strength Evidence for Abstinence:

• Psychostimulants (e.g., dextroamphetamine, methylphenidate, lisdexamfetamine, methamphetamine): 14 RCTs showed improved abstinence (RR 1.36,95% CI 1.05-1.77) 1. Recent evidence suggests these reduce self-reported stimulant use, craving, and depressive symptoms 5. These are legally prescribable off-label under federal law when issued for legitimate medical purposes 5.

• Topiramate: 2 RCTs demonstrated improved abstinence (RR 2.56,95% CI 1.39-4.73) 1, though efficacy was closely tied to concurrent cognitive-behavioral therapy 3.

• Bupropion: 2 RCTs showed increased abstinence (RR 1.63,95% CI 1.02-2.59) 1.

Medications for Treatment Retention (Not Craving):

• Antipsychotics: Moderate-strength evidence for improved retention (8 RCTs: RR 1.33,95% CI 1.03-1.75) 1, but no direct anti-craving effects.

Short-Term Anti-Craving Agents:

Clonidine, fenfluramine, and meta-chlorophenylpiperazine showed promise in short-term treatment 4, though practical utility is limited.

What Doesn't Work

Antidepressants were the most widely studied class (38 RCTs) but show no effect on cocaine use or treatment retention 1. This includes commonly considered agents and represents wasted clinical effort.

Modafinil, despite theoretical appeal, failed to show consistent anti-craving effects in high-quality reviews 4.

Clinical Algorithm

1. First-line: Evidence-based behavioral therapy (contingency management or CBT) combined with pharmacotherapy 6, 2

   • CBT combined with pharmacotherapy is superior to usual care 6
   • Behavioral interventions have the strongest evidence base 2

2. Consider off-label pharmacotherapy for patients not responding to behavioral interventions alone, given:

   • Limited access to intensive behavioral care
   • Relatively low medication risks
   • Significant morbidity of untreated cocaine use disorder 2

3. Medication selection (if pursuing off-label):

   • Psychostimulants (dextroamphetamine, methylphenidate): Best evidence for reducing use and craving 1, 4, 5
   • Topiramate: Only if concurrent structured CBT is available 3
   • Avoid antidepressants: No demonstrated benefit despite extensive testing 1

Critical Caveats

• Craving correlates directly with cocaine use across studies 4, 7, making it a valid treatment target
• Younger age, longer cocaine use history, and higher baseline craving predict worse outcomes 7
• Greater baseline abstinence and treatment engagement predict better outcomes 7
• The heterogeneity of craving assessments across studies limits definitive conclusions 4
• Most positive medication findings come from studies that also included behavioral interventions 6, 2
• Prescribing controlled psychostimulants is federally legal for legitimate medical purposes within professional practice standards 5, despite low current prescribing rates

Bottom Line

Given the absence of FDA-approved options, clinicians should prioritize evidence-based behavioral interventions (particularly contingency management) and consider adding prescription psychostimulants for patients who fail behavioral therapy alone, recognizing this represents off-label use with low-strength supporting evidence 1, 2, 5.